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Abstract
Background: In recent years, there has been an increasing attention to thyroid function in paediatric obese patients. In 
the present study we aimed 1) to determine the prevalence of abnormally elevated thyroid-stimulating hormone (TSH) 
levels in Italian obese children and adolescents 2) to investigate whether hyperthyrotropinemia in obese children 
cardiovascular and metabolic risk factors 3) to verify if TSH elevation is reversible after weight loss.
Methods: We examined 938 obese children and adolescents (450 females). Anthropometric, metabolic and hormonal 
variables were determined at baseline and, in a subgroup of children with hyperthyrotropinemia, after a six month 
weight loss program.
Results: Hyperthyrotropinemia (TSH ≥4.2 μUI/ml) was diagnosed in 120 patients (12,8%). Body mass index (BMI) z-
score (p = 0.02) and free T3 (fT3) levels (p = 0.03) were higher in patients with elevated TSH compared to the group 
with normal TSH. There were not significant differences in other metabolic parameters between the two groups.
A positive correlation between baseline TSH and BMI z-score (p = 0.0045) and between Ft3 and BMI z-score (p =
0.0034) was observed, while there was no correlation between TSH and lipids. Twenty-three patients among those
with hyperthyrotropinemia who participated to weight reduction intervention (64 patients), presented substantial
weight loss and concomitantly a significant decrease in TSH and in fT3.
Conclusions: These results suggest that: (1) a moderate elevation of TSH concentrations, is frequently found in obese 
children; (2) in obese children increase of TSH is not associated to metabolic risk factors, (3) hyperthyrotropinemia is 
reversible after weight loss and these data suggest that it should not be treated.
Background
Obesity is considered a worldwide health problem and its
prevalence is increasing steadily and dramatically all over
the world [1]. Paediatricians are often involved in the ini-
tial evaluation of paediatric obesity and its numerous co-
morbidities. Obese individuals are, in fact, at high risk of
developing dyslipidemia, hypertension and impaired glu-
cose tolerance, with the consequent increase of their risk
of metabolic and cardiovascular diseases [2].
In recent years, there has been an increasing attention
to thyroid function in paediatric obese patients [3].
Hypothyroidism has often been thought to be the cause
of obesity, and thyroid function tests are still now one of
the most commonly performed laboratory analysis in this
population. It has been demonstrated by several studies
that obese children show higher thyroid-stimulating hor-
mone (TSH) levels than normal weight subjects [3-7],
with a higher prevalence of TSH elevation. Isolated
hyperthyrotropinemia is a condition characterized by a
serum TSH above the statistically defined upper limit of
the reference range with normal or slightly high serum
free T4 (fT4) and free T3 (fT3) concentration [8].
Whether or not increased TSH levels affect the metabolic
and cardiovascular profile in obese children and adoles-
cents remains unclear, as well as TSH decrease after
weight loss [6,7]. Thereby, there still is considerable dis-
agreement regarding treatment.
In order to achieve a better understanding of this issue
we aimed 1) to determine the prevalence of hyperthy-
rotropinemia in obese children and adolescents 2) to
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Page 2 of 7investigate whether hyperthyrotropinemia in childhood
obesity is related to dyslipidemia and/or other metabolic
complications 3) to verify whether hyperthyrotropinemia
may reverse after weight loss program. Our series is the
largest published till now.
Methods
We examined 1010 children and adolescents, referred to
our ward (Childhood Obesity Service, Department of
Paediatrics, Second University of Naples) for obesity
between 1999 and 2008. Subjects with known presence of
diabetes or using medications altering blood pressure,
glucose or lipid metabolism, with goitre or known thyroid
disease were excluded (1 subject with type 2 diabetes, 9
with autoimmune thyroiditis). The ethical committee of
the Second University of Study of Naples approved the
study. Informed consent was obtained by parents and,
where appropriate, by children.
Of the 1010 subjects enrolled, 485 were girls. Obesity
was defined according to the body mass index (BMI) 95th
percentile for age and sex using the definition of the
International Task Force for Obesity in Childhood and
the charts for Italian population [9]. Obesity degree was
evaluated using the z-score BMI, calculated with the LMS
method [10].
Anthropometric measures were assessed at the time of
the first visit and in a subgroup of patients with TSH ele-
vation after 6 months.
Waist circumference was measured by the same opera-
tor to the nearest centimetre with a flexible steel tape
measure while the subjects were standing, after gently
exhaling, as the minimal circumference measurable on
the horizontal plane between the lowest portion of the rib
cage and iliac crest. The intra-operator coefficient of vari-
ation was 1,3%.
Standard deviation (SD) scores for waist circumference
have been calculated using normative values for Italian
population [11].
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were measured three times while the subjects
were seated, and the two last measurements were aver-
aged for the analysis and we calculated SD according to
normative values [12].
The pubertal stage was assessed using Tanner criteria
[13].
After an overnight fasting, blood sample were obtained
for triglycerides, high density lipoprotein (HDL) choles-
terol, insulin, serum glucose, thyroid hormones (TSH,
fT3, fT4) and anti-tyreoglobulin (Tg-Ab) and anti-peroxi-
dase anti-bodies (TPO-Ab).
Serum fasting glucose levels were measured with glu-
cose oxidase method. Triglycerides and HDL cholesterol
were measured by an Olympus AU 560 apparatus using
an enzymatic colorimetric method.
Immunoreactive insulin was assayed by IMX (Abbott
Diagnostics, Santa Clara, CA). The mean intra- and inter-
assay coefficients of variations were 4.7% and 7.2%,
respectively. The degree of insulin resistance was deter-
mined using a homeostasis model assessment (HOMA),
[insulin (mU/L) × glucose level(mmol/L)/22.5] [14].
Thyroid hormones (TSH, fT3, and fT4) and TPO-Ab
and Tg-Ab were determined by high-specific solid-phase
technique-chemiluminescenceimmunoassays (Perkinel-
mer, Turku, Finland).
In a subgroup of 160 children we measured leptin
plasma levels using double-antibody radioimmunoassay
(Human Leptin RIA KIT, Linco-Research, St. Charles,
MO). The sensitivity cut-off for the leptin assay was 0.5
ng/ml; the intra and inter-assay variation coefficients
were 10.8% and 7%, respectively.
TPO-Ab and Tg-Ab levels higher than 60 UI/ml were
considered positive, and autoimmune thyroiditis was
diagnosed.
Isolated hyperthyrotropinemia was diagnosed when
TSH was higher than 4.2 μUI/ml (97,5th for our assay),
with normal fT3 and fT4 and no signs or symptoms of
hypothyroidism.
All patients were submitted to a weight loss program.
They consumed a nutritionally balanced (50% carbohy-
drate, 30% fat and 20% protein) self-selected diet of com-
mon foods (80% of the recommended dietary energy
allowances for age and sex). All subjects underwent a life-
style modification program. They followed a program
based on physical exercise, and behavioral therapy,
including individual psychological care of the child and
his or her family. Thyroid hormones and lipids were reas-
sessed after 6 months of the weight reduction program in
patients with elevated TSH levels. Weight reduction was
considered as at least a 0.5 decrease in BMI z-score [15].
All values are expressed as mean ± SD. Skewness and
kurtosis tests were used to evaluate the normal distribu-
tion of the variables. The significance of changes in dis-
crete variables was analyzed by the X2 test.
Mean differences were analyzed with one-way ANOVA
for variables with a normal distribution, and with the
Kruskal-walis test for variables with non Gaussian distri-
bution. Obese children with isolated hyperthyrotropine-
mia, were compared to the obese children with normal
TSH concentrations with respect to peripheral hor-
mones, lipids, HOMA-index, blood pressure and anthro-
pometric measures, and in a subgroup to leptin.
In the patients with hyperthyrotropinemia independent
samples t-test for normal distribution and Mann-Whit-
ney test for parameters with non-Gaussian distribution
were used to compare the changes in the outcome vari-
ables between the group with decrease in BMI z-score
>0.5 point, the one with decrease in BMI z-score between
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z-score.
Linear regression model has been performed to investi-
gate the correlation between TSH and BMI z-score, waist,
lipids, blood pressure and HOMA index (and leptin in
the subgroup in which it was tested).
Multiple linear regression analyses with lipids or blood
pressure as dependent variables and age, gender, degree
of overweight (BMI z-score) pubertal stage, HOMA
index, and thyroid hormones as independent variables
were performed.
Gender and pubertal stage were used as classified vari-
ables. A P < 0.05 was considered statistically significant.
Stat-Graph 3.0 software for Windows was used for the
statistical analysis.
Results
The anthropometric and biochemical characteristics of
patients are shown in Table 1. Overt hypothyroidism was
diagnosed in 12 (1,2%) patients, all with positive thyroidal
auto-antibodies; these patients were excluded from the
analysis.
Other 60 subjects had positive auto-antibodies, 8 of
which with subclinical hypothyroidism, and were all
excluded from the analysis; in total 72 patients (7%) had
autoimmune thyroiditis confirmed by ultrasonography.
Isolated hypethyrotropinemia (TSH≥4.2 μU/l) was
diagnosed in 120 patients (62 girls) of the remaining 938
patients enrolled (12,8%), 70% were prepubertal. There
were no significant differences by sex and pubertal stage
(p = 0.2 and p = 0.4 respectively) compared to those with
normal TSH levels.
Obese children with and without hyperthyrotropine-
mia had fT3 and fT4 concentrations within the normal
range and did not differ significantly in their fT4, lipid
concentrations, HOMA values and blood pressure com-
pared to those with TSH in the normal range (Table 2).
All analysis were adjusted for age, sex and pubertal stage.
Table 1: Anthropometric, clinical and biochemical characteristics at baseline of 938 obese children involved in the study.
Mean ± SD Range
N 938
Prepubertal (%) 572 (61%)
Age (yr) 10.3 ± 2.6 4.5-15.9
Gender 48% girls
BMI z-score 2.9 ± 0.7 1.8-5.8
Waist SD 3.7 ± 2.3 0-11
SBP SD 0.7 ± 1.1 -1.5-4.6
DBP SD 0.2 ± 0.7 -1.3-2.7
TSH (micrUI/ml) 2.6 ± 1.2 0.2-8.5
fT3 (pg/ml) 3.8 ± 0.8 1.1-7.1
fT4 (pg/ml) 10.3 ± 1.6 6.2-15.9
HDL (mg/dl) 45 ± 9.5 28-82
Triglycerides (mg/dl) 91.2 ± 44 50-198
HOMA 7.3 ± 5.4 1.1-18
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higher (p:0.03) in patients with elevated TSH, while their
age was significantly lower (p:0,0007).
In all the 938 patients enrolled a positive correlation
between baseline TSH and BMI z-score (p = 0.0045) and
between Ft3 and BMI z-score (p = 0.0034), adjusted for
age, gender and pubertal stage, was observed.
In a multiple regression analysis adjusted for age, gen-
der, pubertal age, degree of overweight and HOMA, there
was no significant correlation between TSH and HDL
(p:0,6), triglycerides (p:0,5), blood pressure (p:0,5) as well
as between fT3 and HDL (p:0,5), triglycerides (p:0,6),
blood pressure (p:0,5) as well as between fT4 and all the
mentioned parameters.
In a subgroup (160 patients), randomly selected, we
measured plasma leptin. Among this subgroup 22
patients had isolated TSH elevation and their leptin levels
were not different from those with normal TSH, adjusting
for BMI z-score. Moreover in all 160 patients we did not
find any correlation between leptin and TSH, also adjust-
ing for gender, pubertal stage and degree of overweight
(data not shown).
A total of 64 patients with elevated TSH levels com-
pleted (53%) the weight reduction intervention. No dif-
ference in the baseline characteristics were found
between patients who dropped out and those who did
not. Among these 64 patients, 23 patients presented a
substantial weight loss, defined as a decrease at least in
0.5 points of their BMI z-score [15]. Twenty-one patients
presented a decrease in BMI z-score between 0.2 and 0.5
points, while the other 20 did not loose weight.
Compared to their baseline parameters, patients who
lost substantially weight presented a statistically signifi-
cant decrease in TSH and in fT3 and improvement in
lipid profile; such improvement did not significantly cor-
relate to thyroid hormones after adjusting for changes in
BMI (Table 3).
Patients without weight loss, or with a weight loss less
than 0.5 points in their BMI z-score, on the contrary, did
not show any difference in TSH and in fT3 levels com-
pared to the values before the weight loss program (Table
3).
Table 2: Anthropometric, clinical and biochemical characteristics of obese patients with hyperthyrotropinemia compared 
to those with normal TSH.
TSH ≥4.2 micrUI/ml TSH <4.2 micrUI/ml P value
N 120 (12.7%) 818
Age (yr) 9.7 ± 2.7 10.4 ± 2.6 0.0007
Gender 52% girls 47% girls >0.05
BMI z-score 3.1 ± 1 2.8 ± 0.7 0.02
Waist SD 3.4 ± 2.2 3.5 ± 2.2 >0.05
SBP SD 0.9 ± 1.2 0.7 ± 1.1 >0.05
DBP SD 0.17 ± 0.8 0.16 ± 0.7 >0.05
TSH (μUI/ml) 5.1 ± 1 2.3 ± 0.8 <0.00001
fT3 (pg/ml) 4 ± 0.9 3.8 ± 0.8 0.03
fT4 (pg/ml) 10.3 ± 1.8 10 ± 1.7 >0.05
HDL (mg/dl) 45.5 ± 9 43.7 ± 9 >0.05
Triglycerides (mg/dl) 94 ± 44 87 ± 38 >0.05
HOMA 7.7 ± 4.6 7.1 ± 5 >0.05
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The relationship between obesity and thyroid dysfunc-
tion is a topic of great interest, as a large number of obese
children now seeking medical care.
Isolated TSH elevation has been demonstrated to be
quite frequent in obese children, but it is not clear if such
condition is associated to increased cardiovascular risk
factors, if it reverses after weight loss, and, therefore,
there is general disagreement regarding whether and
when to start treatment with L-thyroxin [6,7,16].
We believe our series is the larger than any other pub-
lished report.
In agreement with other studies, isolated hyperthy-
rotropinemia is quite common in our sample of obese
children (12,8%), [3,5-7,17]; a limitation of our study is
lacking of a control group, anyway prevalence of isolated
hyperthyrotropinemia in our sample is higher compared
to the prevalence observed in normal weight subjects
(2%), even if epidemiological data on lean children and
adolescents are scarce [18-20].
Thyroiditis appears to occur frequently in our sample
of obese subjects (7%) compared to the reported preva-
lence of 1.2% in normal weight children [21]. This condi-
tion, therefore, should always be excluded when obese
patients show elevated TSH levels; in the present study
most part of obese subjects with hyperthyrotropinemia
(120 out of 128, i.e. 93.7%) did not have thyroiditis.
The reason of the increase of TSH in obese subjects,
both adults and children, is not clear.
Patients with higher levels of TSH had a lower mean
age, but the trend of TSH to decrease with age is well
known and described [20]. Furthermore, this trend does
not affect statistical results as every analysis has been
adjusted for age.
We found a direct correlation between TSH and BMI-
z-score and between fT3 and BMI-z-score; this relation-
ship could suggest an association with leptin, which is
regulated by body adiposity [22]. Furthermore, there is a
synchronicity between the secretion of leptin and TSH
[23]. A recent report demonstrated that TSH is related
both to BMI and to leptin in obese and anorexic patients
[24]. However a previous study had shown no correlation
between TSH and leptin [25]. We failed to demonstrate
an association between leptin and TSH, probably due the
homogeneity of the weight status of our patients (we
studied only obese subjects). Furthermore, considering
that TSH production is regulated by several transmitters
and hormones which regulates also body weight and sati-
ation, such as neuropeptide Y, alpha-melanocyte-stimu-
lating hormone and leptin itself [26,27], a mechanism of
regulation of TSH more complicated than a simple linear
association among TSH and leptin levels, could be
inferred to explain this lack of association. For example a
tissue-specific modulation of deiodinases at pituitary
Table 3: Degree of overweight, thyroid hormones and lipids concentrations in obese children with hyperthyrotropinemia 
before and after weight loss program.
Decrease in BMI-SDS >0.5 Decrease in BMI-SDS 0.2-0.5 No weight loss
N 23 21 20




p Baseline Six months 
later
p Baseline Six months 
later
p
BMI z-score 2.9 ± 1.3 2.0 ± 1 0.007 2.8 ± 0.5 2.5 ± 0.6 0.3 2.7 ± 0.5 2.7 ± 0.6 0.4
TSH (μUI/ml) 5.1 ± 1 3.6 ± 1.1 0.0001 5.2 ± 0.9 4.6 ± 2.6 0.3 5.27 ± 1.3 4.6 ± 2.6 0,4
fT3 (pg/ml) 3.9 ± 1 3.4 ± 0.5 0.03 3.7 ± 0.7 4 ± 0.2 0.1 3.8 ± 0.7 4.4 ± 0.2 0.09
fT4 (pg/ml) 9.8 ± 2.5 8.8 ± 2.9 0.1 9.8 ± 2.5 10.2 ± 1.8 0.1 10 ± 2 10.3 ± 1.6 0.8
HDL (mg/dl) 40 ± 23 45 ± 14 0.6 37 ± 21 39 ± 14 0.8 37 ± 15 38 ± 13 0.9
Triglycerides 
(mg/dl)
101 ± 39 90 ± 40 0.6 103 ± 85 98 ± 34 0.9 108 ± 61 98 ± 65 0.8
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function. Studies in animal models show that leptin
administration can decrease D2 deiodinase activity in
pituitary tissue, thus modifying the feedback of T3 on
TSH secretion [28].
In some studies subclinical hypothyroidism has been
shown to worsen metabolic profile, causing dyslipidemia
or heart dysfunction [29,30]. However there is no agree-
ment on this point and many studies are on adult
patients.
Obese children are at increased metabolic risk, because
they can present insulin resistance, hypertension or dys-
lipidemia [2].
We show that obese children with isolated elevation of
TSH do not have an increase in their metabolic risk fac-
tors and demonstrate no significant relationship between
TSH levels and lipids, blood pressure and insulin resis-
tance.
These findings are in agreement with some other stud-
ies in adults and children [5,31].
After substantial weight reduction, TSH and fT3 lower
significantly and normalize, in accordance with a previ-
ous study by Reinehr and in contrast with a recent study
by Shalitin et al [5,7]. Slight reduction in weight, that is a
decrease in BMI z-score of less than 0.5 points, is not
associated to TSH normalization, suggesting that a
weight reduction able to modify insulin resistance and
cardiovascular risk factor is needed to influence thyroid
hormone metabolism.
Obese patients have with hyperthyrotropinemia have
fT3 levels significantly higher compared to obese children
with normal TSH levels. This finding confirms the theory
that the negative feedback between TSH and the periph-
eral hormones is decreased. Furthermore, fT3 levels
diminish after weight loss. These findings can suggest
another observation about pathogenesis. Thyroid hor-
mones, especially fT3, regulate the resting energy expen-
diture (REE). In obese patients the moderate increase in
fT3 and TSH lead to an increase of energy expenditure.
As a consequence of this, the availability of accumulated
energy for conversion into fat is diminished [32]. The
alterations of thyroid hormones in obesity have been sug-
gested to be an adaptation process.
If this hypothesis is true, the possibility exists that, as
weight loss is associated with a decrease of TSH and fT3,
the resulting decrease in REE may contribute towards the
difficulties of obese children in maintaining weight loss
[8].
Conclusions
In summary, a moderate elevation of TSH concentration
is frequently found in obese children and is not associ-
ated to increased metabolic risk.
This condition seems rather a consequence than a
cause of obesity since weight loss leads to a normalization
of elevated thyroid hormone levels.
There is diffuse disagreement about the management of
hyperthyrotropinemia both in adults and children. In
particular we lack of large studies that demonstrate
advantages to treat children showing TSH between 5 and
10 μU/ml [33].
Considering our results we suggest that obese children
with this condition should not be treated under the "diag-
nosis" of subclinical hypothyroidism because TSH altera-
tion is more a consequence than a cause of obesity.
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